Nasal vaccines for pertussis

IF 6.6 2区医学 Q1 IMMUNOLOGY

Current Opinion in Immunology Pub Date : 2023-10-01 DOI:10.1016/j.coi.2023.102355

Pauline Schmitt , Lisa Borkner , Seyed Davoud Jazayeri , Karen N McCarthy , Kingston HG Mills

引用次数: 0

Abstract

Whooping cough, caused by Bordetella pertussis, is still a major cause of morbidity and mortality worldwide. Current acellular pertussis (aP) vaccines induce potent circulating IgG and prevent severe disease in children/adults and in infants born to vaccinated mothers. However, they do not prevent nasal infection, allowing asymptomatic transmission of B. pertussis. Studies in animal models have demonstrated that, unlike natural infection, immunization with aP vaccines fails to induce secretory immunoglobulin A (IgA) or interleukin-17 (IL-17)-secreting tissue-resident memory CD4 T (T_RM) cells, required for sustained sterilizing immunity in the nasal mucosa. Live-attenuated vaccines or aP vaccines formulated with novel adjuvants that induce respiratory IgA and T_RM cells, especially when delivered by the nasal route, are in development and have considerable promise as next-generation vaccines against pertussis.

Abstract Image

查看原文本刊更多论文

百日咳鼻用疫苗。

百日咳杆菌引起的百日咳仍然是全世界发病率和死亡率的主要原因。目前的无细胞百日咳（aP）疫苗可诱导有效的循环IgG，并可预防儿童/成人和接种疫苗的母亲所生婴儿的严重疾病。然而，它们不能预防鼻腔感染，从而导致百日咳杆菌的无症状传播。动物模型研究表明，与自然感染不同，aP疫苗免疫不能诱导分泌型免疫球蛋白A（IgA）或白细胞介素17（IL-17）分泌的组织驻留记忆CD4 T（TRM）细胞，这是鼻粘膜持续杀菌免疫所必需的。减毒活疫苗或由诱导呼吸道IgA和TRM细胞的新型佐剂配制的aP疫苗，特别是当通过鼻腔途径递送时，正在开发中，作为下一代百日咳疫苗具有相当大的前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Immunology 医学-免疫学

CiteScore

13.30

自引率

1.40%

发文量

审稿时长

67 days

期刊介绍： Current Opinion in Immunology aims to stimulate scientifically grounded, interdisciplinary, multi-scale debate and exchange of ideas. It contains polished, concise and timely reviews and opinions, with particular emphasis on those articles published in the past two years. In addition to describing recent trends, the authors are encouraged to give their subjective opinion of the topics discussed. In Current Opinion in Immunology we help the reader by providing in a systematic manner: 1. The views of experts on current advances in their field in a clear and readable form. 2. Evaluations of the most interesting papers, annotated by experts, from the great wealth of original publications. Current Opinion in Immunology will serve as an invaluable source of information for researchers, lecturers, teachers, professionals, policy makers and students. Current Opinion in Immunology builds on Elsevier''s reputation for excellence in scientific publishing and long-standing commitment to communicating reproducible biomedical research targeted at improving human health. It is a companion to the new Gold Open Access journal Current Research in Immunology and is part of the Current Opinion and Research(CO+RE) suite of journals. All CO+RE journals leverage the Current Opinion legacy-of editorial excellence, high-impact, and global reach-to ensure they are a widely read resource that is integral to scientists'' workflow.